1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Viva Biotech Holdings

Viva Biotech Holdings

1873.HK
Viva Biotech HoldingsHK flagHong Kong Stock Exchange
1.21
HKD
- -
- -
2.51BMarket Cap
Viva Biotech Holdings
1873.HK
(Hong Kong Stock Exchange)

Recent

price

1.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.06
0.1
0.14
0.23
0.44
1.1
1.24
1.06
0.93
0.82
Revenue per Share
0.02
0.05
0.06
0.19
-0.25
0.15
-0.28
-0.06
0.08
0.1
Basic EPS, GAAP
0.01
0.01
-0.02
-0.01
-0.37
-0.26
0.07
0.1
0.09
0.05
Free Cash Flow per Basic Share
- -
- -
- -
0.1
0.03
0.01
- -
- -
- -
- -
Dividend per Share
0.01
0.06
0.11
0.3
0.02
0.14
-0.14
-0.21
-0.13
-0.04
Book Value per Share
0.05
0.1
0.17
1.27
0.92
0.64
0.51
0.55
0.61
0.73
Tangible Book Value per Share
1,500
1,500
1,500
1,400
1,572
1,912
1,915
2,029
2,137
2,111
Basic Weighted Avg Shares
96
148
210
323
697
2,104
2,380
2,156
1,987
1,729
Sales/Revenue/Turnover
30.13
38.74
14.4
13.62
17.94
12.82
13.11
11.88
13.57
12.24
Operating Margin (%)
4
6
10
34
70
153
185
211
214
211
Depreciation Expense
24
76
91
266
-387
288
-528
-116
167
220
Net Income, GAAP
13.89
12.15
14.46
5.36
- -
13.56
- -
- -
24.93
15.33
Effective Tax Rate (%)
25.36
51.44
43.11
82.3
-55.51
13.67
-22.21
-5.39
8.42
12.71
Profit Margin (%)
49
46
199
1,021
2,616
1,057
-734
497
628
717
Working Capital
3
2
2
24
2,803
2,416
907
951
732
358
LT Debt
77
153
251
1,777
3,757
3,913
3,605
3,688
3,816
4,006
Total Equity
- -
39.01
11.67
3.96
- -
3.48
- -
- -
3.77
3.42
Return on Invested Capital (%)
- -
132.65
67.77
83.27
- -
14.62
- -
- -
12.26
17.86
Return on Capital (%)
- -
156.18
72.05
89.84
-172.66
193.25
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.41%
4.98%
Free Cash Flow
- -
-29.26%
-39.84%
Net Income, GAAP
- -
-149.77%
31.36%
Sales/Revenue/Turnover
- -
36.96%
-12.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,156
2024
- -
- -
- -
- -
1,987
2025
- -
- -
- -
- -
1,729

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.06
2024
- -
- -
- -
- -
0.08
2025
- -
- -
- -
- -
0.1

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Hansa Biopharma AB (publ) (0RC7.L)
Moleculin Biotech, Inc. (MBRX)
MedinCell S.A. (MDCLF)
Aptahem AB (publ) (APTA.ST)
Dishman Carbogen Amcis Limited (DCAL.NS)
Moderna, Inc. (MRNA)
Business
Viva Biotech Holdings (1873.HK) is a China-based investment holding company principally engaged in providing structure-based drug discovery (SBDD) and contract development and manufacturing organization (CDMO) services to global biotechnology and pharmaceutical customers for preclinical and innovative drug development programs. Founded in 2008 and headquartered in Shanghai, China, the company offers comprehensive one-stop solutions including protein expression, purification and structural biology using X-ray crystallization and Cryo-EM; hit discovery via DEL, ASMS screening, fragment-based drug discovery (FBDD) and affinity selection; bioassays, biomolecular interactions, ADME/PK studies; therapeutic antibody discovery, expression and production; computer-aided drug design (CADD/AIDD), medicinal chemistry from hit-to-lead optimization, custom synthesis, chemical analysis, purification and kilogram-scale up; PROTAC/molecular glue and XDC platforms; as well as small molecule active pharmaceutical ingredients (API) development, formulation, GMP-compliant manufacturing through subsidiary Langhua Pharma, and CMC filing support; alongside an equity-for-service (EFS) model investing in high-potential biotech startups. It operates primarily in the United States, China, Europe and other regions, serving biopharma innovators across small molecules and biologics modalities with laboratories in Shanghai, Jiaxing, Suzhou and Chengdu. Recent developments include CRO revenue returning to positive growth in the 2025 interim period driven by AI-enabled initiatives contributing nearly 10% of revenue and strategic alliances with domestic pharmaceutical firms; enhanced CDMO profitability with preparations for new commercial projects and PPQ production underway following full acquisition of Zhejiang Langhua Pharmaceutical; portfolio companies raising approximately US$293.6 million with 228 pipeline projects and 18 investment exits; new investments in assets like Kriya, Piara, Bioabs, Dogma, Arrosia, Basking, Cybrexa and FuseBio; establishment of an RMB 250 million biopharmaceutical investment fund via subsidiary Hangzhou Viva Zongchen in May 2025; and restructuring of Viva Biotech Shanghai into a joint stock limited company in September 2024.